Connect Biopharma Holdings Limited Ordinary Shares

Connect Biopharma reported Q1 2026 financial results and provided updates on its Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD. The independent Data Monitoring Committee confirmed no safety concerns and adequate study power, with topline data expected mid-2026. The company closed a $20.2 million private placement and h...

Connect Biopharma will present two poster presentations at the ERS Congress 2025 about rademikibart, a monoclonal antibody targeting IL-4Rα for treating asthma and inflammatory diseases.

Connect Biopharma reported a significant revenue drop from $24.1 million to $48,000 in Q2 2025, increased R&D expenses, and a net loss of $12.9 million. The company continues developing rademikibart for inflammatory diseases and is progressing clinical trials.

Connect Biopharma will present at the BTIG Virtual Biotechnology Conference on July 29th, 2025, discussing their clinical-stage development of rademikibart, an antibody targeting IL-4Rα for treating asthma and COPD.

Connect Biopharma presented positive data on its investigational drug rademikibart, which showed significant improvements in lung function and reduced asthma exacerbations in patients with eosinophilic-driven type 2 asthma.